1 citations
,
January 2012 in “Daehan namseong gwahag hoeji” Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
April 2013 in “The Journal of Urology” Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.
3 citations
,
October 2011 in “QJM” The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
24 citations
,
January 1996 in “The Prostate” Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
January 2012 in “Земский врач” Finasteride helps improve treatment for benign prostatic hyperplasia.
April 2012 in “The Journal of Urology” PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
September 2009 in “European Urology Supplements” After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.
16 citations
,
January 2000 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.
6 citations
,
July 2016 in “Gynecological Endocrinology” PSA levels are higher in women with PCOS, but FAI is a more accurate marker for diagnosis.
September 2011 in “Urology” Urinary PSA could be an early marker for enlarged prostate.
June 2007 in “Nature Clinical Practice Urology” Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.
March 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
18 citations
,
March 2008 in “British Journal of Dermatology” Finasteride works better for hair loss in patients 26 or younger.
April 2013 in “The Journal of Urology” Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.
October 2010 in “Journal of Men's Health” Larger prostate size in older men may be linked to poorer semen quality and fertility issues.
49 citations
,
August 2009 in “British Journal of Cancer” Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.
20 citations
,
June 2017 in “Hormone Molecular Biology and Clinical Investigation” Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
9 citations
,
September 2010 in “Dermatologic Therapy” Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.
1 citations
,
May 2024 in “Human Genomics” Polygenic risk scores can predict the risk and outcomes of benign prostatic hyperplasia.
April 2022 in “Diabetes Therapy” Low testosterone does not prevent prostate cancer in men with type 1 diabetes.
195 citations
,
February 2007 in “The Journal of Clinical Endocrinology and Metabolism” Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.
109 citations
,
April 2000 in “European Urology” Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
89 citations
,
December 2006 in “Lancet Oncology” Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.
72 citations
,
April 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
39 citations
,
November 2017 in “Journal of The American Academy of Dermatology” The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
23 citations
,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.